PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 109 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs June 25, 2020 Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 Load more HOT NEWS Dr Ian Walker on Smoking: ‘The killer behind the counter’ Satisfying Snacks FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher...
